The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

Yinon Ben-Neriah*, George Q. Daley, Anne Marie Mes-Masson, Owen N. Witte, David Baltimore

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

695 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is a human disease associated with a consistent chromosomal translocation mat results in sequences from the c-abl locus on chromosome 9 being fused to sequences in a breakpoint chuter region (bcr) on chromosome 22. CML cells have two novel products: an 8.5-kilobase RNA transcript containing both abl and bcr and a 210-kilodalton phosphoprotein (P210) recognized by v-abl-specific antisera. To test whether the P210 is the product of the novel 8.5-kilobase bcr/abl fusion transcript, antibodies were prepared against c-abl and bcr determinants. By using these reagents and v-abl-specific antisera, it was demonstrated that the P210 in CML cells is indeed the protein product of the 8.5-kilobase transcript. By analogy to the gag/abl fusion protein of Abelson murine leukemia virus, the replacement of amino terminal c-abl sequences by bcr sequences in P210 may create a transforming protein involved in CML. A 190-kilodalton phosphoprotein that is a candidate for the normal bcr protein was identified in both HeLa and K562 cells.

Original languageAmerican English
Pages (from-to)212-214
Number of pages3
JournalScience
Volume233
Issue number4760
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Dive into the research topics of 'The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene'. Together they form a unique fingerprint.

Cite this